The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Rani Therapeutics Holdings 9-Day RSI Related Terms
RANI vs IBIO, RNTX, OSTX: 9-Day RSI Comparison
For the Biotechnology subindustry, Rani Therapeutics Holdings's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rani Therapeutics Holdings 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rani Therapeutics Holdings's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Rani Therapeutics Holdings's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rani Therapeutics Holdings (RANI) has a 9-Day RSI of 43.51 as of Jul. 02, 2026. According to the industry distribution chart, Rani Therapeutics Holdings ranks #444 out of 1422 companies in the Biotechnology industry, placing it in the top 31.2%.
Is Rani Therapeutics Holdings' 9-Day RSI too high?
Rani Therapeutics Holdings' current 9-Day RSI is 43.51. The Biotechnology industry median 9-Day RSI is 50.36. Rani Therapeutics Holdings' value of 43.51 is 13.6% below this industry median. Based on the distribution chart, Rani Therapeutics Holdings ranks #444 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Rani Therapeutics Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Rani Therapeutics Holdings' 9-Day RSI compare to IBIO and RNTX?
According to the Biotechnology industry distribution chart, Rani Therapeutics Holdings ranks #444 out of 1422 companies for 9-Day RSI. This puts Rani Therapeutics Holdings in the upper half of its industry. The industry median 9-Day RSI is 50.36. Rani Therapeutics Holdings' value of 43.51 is 13.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 50.36, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rani Therapeutics Holdings's current 9-Day RSI of 43.51 is 13.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 50.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rani Therapeutics Holdings's current 9-Day RSI is 43.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rani Therapeutics Holdings stock overvalued right now?
Rani Therapeutics Holdings (RANI) has a current 9-Day RSI of 43.51. The current 9-Day RSI is 43.51 and 13.6% below the Biotechnology industry median of 50.36. Rani Therapeutics Holdings' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Rani Therapeutics Holdings (RANI), the current 9-Day RSI is 43.51 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
32GF Score
Get the complete analysis for RANI
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RANI has been successfully added to your 